MX389312B - Promotores para mejorar la expresion en poxvirus. - Google Patents
Promotores para mejorar la expresion en poxvirus.Info
- Publication number
- MX389312B MX389312B MX2018001055A MX2018001055A MX389312B MX 389312 B MX389312 B MX 389312B MX 2018001055 A MX2018001055 A MX 2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A MX 389312 B MX389312 B MX 389312B
- Authority
- MX
- Mexico
- Prior art keywords
- poxvirus
- promoters
- expression
- enhance expression
- enhance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199681P | 2015-07-31 | 2015-07-31 | |
| PCT/IB2016/001183 WO2017021776A1 (en) | 2015-07-31 | 2016-07-28 | Promoters for enhancing expression in poxviruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001055A MX2018001055A (es) | 2018-05-17 |
| MX389312B true MX389312B (es) | 2025-03-20 |
Family
ID=57068152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001055A MX389312B (es) | 2015-07-31 | 2016-07-28 | Promotores para mejorar la expresion en poxvirus. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11753652B2 (https=) |
| EP (1) | EP3329016B1 (https=) |
| JP (1) | JP6851364B2 (https=) |
| KR (1) | KR102565284B1 (https=) |
| CN (1) | CN107922981B (https=) |
| AU (1) | AU2016303378B2 (https=) |
| CA (1) | CA2990549A1 (https=) |
| DK (1) | DK3329016T3 (https=) |
| ES (1) | ES2901468T3 (https=) |
| IL (1) | IL256869B (https=) |
| MX (1) | MX389312B (https=) |
| RU (1) | RU2753884C2 (https=) |
| SG (1) | SG10202000447YA (https=) |
| WO (1) | WO2017021776A1 (https=) |
| ZA (1) | ZA201800104B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102754876B1 (ko) | 2017-08-24 | 2025-01-13 | 버베리안 노딕 에이/에스 | 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법 |
| CN111741766A (zh) | 2017-12-19 | 2020-10-02 | 杨森科学爱尔兰无限公司 | 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| MX2021005560A (es) | 2018-11-20 | 2021-06-23 | Bavarian Nordic As | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). |
| CN114867491B (zh) | 2019-11-20 | 2025-08-15 | 巴法里安诺迪克有限公司 | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 |
| EP4452305A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| US20250049903A1 (en) | 2021-12-23 | 2025-02-13 | Bavarian Nordic A/S | Therapy for Modulating Immune Response with Recombinant MVA Encoding IL-12 |
| EP4648781A1 (en) | 2023-01-12 | 2025-11-19 | Bavarian Nordic A/S | Recombinant modified sarna (vrp) for cancer vaccine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| EP1380651A2 (en) * | 1991-08-26 | 2004-01-14 | Baxter Healthcare S.A. | Recombinant fowlpox virus with intact FPV-tk-gene |
| CA2261989C (en) | 1996-07-25 | 2008-09-30 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| RU2180352C2 (ru) | 1999-11-24 | 2002-03-10 | Государственный научный центр вирусологии и биотехнологии "Вектор" | ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР |
| EP1601333B1 (en) * | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| CA2542155A1 (en) | 2003-10-15 | 2005-04-28 | Virax Development Pty Ltd | Poxvirus vector encoding retrovirus (eg hiv) and cytokine |
| EP2125868B1 (en) * | 2007-02-28 | 2015-06-10 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| CN101775410B (zh) | 2009-01-09 | 2011-11-16 | 中国人民解放军军事医学科学院军事兽医研究所 | 一种鸡痘病毒载体穿梭质粒及其应用 |
| KR101781966B1 (ko) * | 2009-04-17 | 2017-09-27 | 글로브이뮨 | 암에 대한 병용 면역요법 조성물 및 방법 |
| CN102321637A (zh) | 2011-09-09 | 2012-01-18 | 中国人民解放军军事医学科学院军事兽医研究所 | 中国鸡痘病毒282e4弱毒株全基因组序列及其应用 |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
-
2016
- 2016-07-28 JP JP2018500943A patent/JP6851364B2/ja active Active
- 2016-07-28 CA CA2990549A patent/CA2990549A1/en active Pending
- 2016-07-28 US US15/747,844 patent/US11753652B2/en active Active
- 2016-07-28 KR KR1020187000086A patent/KR102565284B1/ko active Active
- 2016-07-28 WO PCT/IB2016/001183 patent/WO2017021776A1/en not_active Ceased
- 2016-07-28 AU AU2016303378A patent/AU2016303378B2/en active Active
- 2016-07-28 DK DK16775852.3T patent/DK3329016T3/da active
- 2016-07-28 EP EP16775852.3A patent/EP3329016B1/en active Active
- 2016-07-28 MX MX2018001055A patent/MX389312B/es unknown
- 2016-07-28 IL IL256869A patent/IL256869B/en unknown
- 2016-07-28 SG SG10202000447YA patent/SG10202000447YA/en unknown
- 2016-07-28 CN CN201680042251.3A patent/CN107922981B/zh active Active
- 2016-07-28 RU RU2018106643A patent/RU2753884C2/ru active
- 2016-07-28 ES ES16775852T patent/ES2901468T3/es active Active
-
2018
- 2018-01-05 ZA ZA2018/00104A patent/ZA201800104B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ738713A (en) | 2024-11-29 |
| KR102565284B1 (ko) | 2023-08-08 |
| AU2016303378B2 (en) | 2021-12-23 |
| EP3329016A1 (en) | 2018-06-06 |
| CN107922981A (zh) | 2018-04-17 |
| RU2753884C2 (ru) | 2021-08-24 |
| SG10202000447YA (en) | 2020-03-30 |
| WO2017021776A1 (en) | 2017-02-09 |
| IL256869A (en) | 2018-03-29 |
| US20180216134A1 (en) | 2018-08-02 |
| CN107922981B (zh) | 2022-02-25 |
| AU2016303378A1 (en) | 2018-01-25 |
| BR112018002172A2 (pt) | 2018-09-18 |
| HK1254405A1 (en) | 2019-07-19 |
| ZA201800104B (en) | 2022-04-28 |
| JP6851364B2 (ja) | 2021-03-31 |
| IL256869B (en) | 2022-07-01 |
| CA2990549A1 (en) | 2017-02-09 |
| EP3329016B1 (en) | 2021-10-20 |
| KR20180033498A (ko) | 2018-04-03 |
| US11753652B2 (en) | 2023-09-12 |
| DK3329016T3 (da) | 2022-01-10 |
| MX2018001055A (es) | 2018-05-17 |
| RU2018106643A3 (https=) | 2020-01-30 |
| BR112018002172A8 (pt) | 2024-02-15 |
| JP2018521651A (ja) | 2018-08-09 |
| RU2018106643A (ru) | 2019-08-28 |
| ES2901468T3 (es) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389312B (es) | Promotores para mejorar la expresion en poxvirus. | |
| CO2019013609A2 (es) | Vectores de neoantígeno de alfavirus | |
| MX2019011040A (es) | Composiciones y metodos para potenciar la expresion genica. | |
| CO2019006541A2 (es) | Administración viral de neoantígenos | |
| MX2017005958A (es) | Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas. | |
| MX378913B (es) | Células para inmunoterapia diseñadas para dirigir antígeno presente tanto en células inmunes y células patológicas. | |
| MX2018000845A (es) | Vector vírico orf recombinante. | |
| MX2017009953A (es) | Regulacion de la expresión génica a través de la modulación mediada por un aptámero del empalme alternativo. | |
| MX382223B (es) | Regulacion de expresion genica mediada por nucleasa. | |
| MX2022006513A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
| BR112018002600A2 (pt) | células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38 | |
| CL2017003096A1 (es) | Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis | |
| MX391694B (es) | Elementos regulatorios post-transcripcionales modificados de hepatitis. | |
| MX384795B (es) | Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso. | |
| AR103553A1 (es) | Promotor y usos del mismo | |
| GT201500004S (es) | Diseño de carro de juguete (diseño fraccionario de la solicitud no. s-201500004) | |
| MX2019008359A (es) | Cadena j modificada. | |
| MX2021009309A (es) | Modulacion de la actividad del complemento. | |
| UY35385A (es) | ?métodos y composiciones para el control de malezas?. | |
| GT201600066A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
| MX2016013849A (es) | Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende. | |
| MX2017008587A (es) | Mirna natural para controlar la expresion de gen y uso del mismo. | |
| MX2018004063A (es) | Secuencias recombinantes de cromosoma b de maíz y sus usos. | |
| CL2018003649A1 (es) | Edición genética mejorada | |
| MX382997B (es) | Composiciones y metodos para mejorar la expresion genetica de pklr. |